|Bid||14.01 x 3200|
|Ask||14.02 x 800|
|Day's range||13.89 - 14.02|
|52-week range||13.05 - 17.31|
|Beta (5Y monthly)||0.80|
|PE ratio (TTM)||29.81|
|Forward dividend & yield||0.80 (5.81%)|
|Ex-dividend date||29 Sept 2021|
|1y target est||21.02|
TAK vs. ZTS: Which Stock Is the Better Value Option?
The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OSAKA, Japan, July 28, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year management guidance.